£3.7M
Oxford Science Enterprises led the seed round to support expansion across formulation development and data science.
Allos
Allos applies causal artificial intelligence to reformulate complex generic drugs and improve patient medicines.
£3.7MTotal raised
Allos applies causal artificial intelligence to commercialise a platform for the end-to-end reformulation of complex generic drugs and next-generation medicines. The company helps developers modernise legacy pharmaceutical assets and reduce clinical uncertainty.
Filed accounts
Cash at bank
Members only
Net current assets
Members only
Net assets
Members only
Shareholders' funds
Members only
Current assets
Members only
Employees
Members only
Cash, assets and headcount from Allos's latest Companies House filing — with year-on-year movement, free with a Winfred account.
Categories
Founders
Aditya Iyer
CEO and co-founder
Aditya brings research experience from CERN and the University of Oxford, alongside his role as chief executive and co-founder of Allos.
LinkedIn